Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial
Background: Approximately one in five cancer patients use proton pump inhibitors (PPIs). In this work, we studied the effect of PPI co-medication during neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC) based on the phase III PRODIGE 23 trial. Materials and methods: We g...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Elsevier
2025-03-01
|
| Sraith: | ESMO Gastrointestinal Oncology |
| Ábhair: | |
| Rochtain ar líne: | http://www.sciencedirect.com/science/article/pii/S2949819824000803 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|